1. Home
  2. RDHL vs BREA Comparison

RDHL vs BREA Comparison

Compare RDHL & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • BREA
  • Stock Information
  • Founded
  • RDHL 2009
  • BREA 2022
  • Country
  • RDHL Israel
  • BREA Ireland
  • Employees
  • RDHL N/A
  • BREA N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • BREA Services-Misc. Amusement & Recreation
  • Sector
  • RDHL Health Care
  • BREA Consumer Discretionary
  • Exchange
  • RDHL Nasdaq
  • BREA Nasdaq
  • Market Cap
  • RDHL 8.2M
  • BREA 8.7M
  • IPO Year
  • RDHL N/A
  • BREA 2023
  • Fundamental
  • Price
  • RDHL $5.60
  • BREA $0.63
  • Analyst Decision
  • RDHL
  • BREA
  • Analyst Count
  • RDHL 0
  • BREA 0
  • Target Price
  • RDHL N/A
  • BREA N/A
  • AVG Volume (30 Days)
  • RDHL 10.5K
  • BREA 42.1K
  • Earning Date
  • RDHL 04-07-2025
  • BREA 01-03-2025
  • Dividend Yield
  • RDHL N/A
  • BREA N/A
  • EPS Growth
  • RDHL N/A
  • BREA N/A
  • EPS
  • RDHL N/A
  • BREA N/A
  • Revenue
  • RDHL $3,707,000.00
  • BREA $2,872,101.00
  • Revenue This Year
  • RDHL $224.90
  • BREA N/A
  • Revenue Next Year
  • RDHL $82.69
  • BREA N/A
  • P/E Ratio
  • RDHL N/A
  • BREA N/A
  • Revenue Growth
  • RDHL N/A
  • BREA 2338.69
  • 52 Week Low
  • RDHL $5.41
  • BREA $0.50
  • 52 Week High
  • RDHL $20.28
  • BREA $3.00
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 38.40
  • BREA 39.55
  • Support Level
  • RDHL $5.52
  • BREA $0.60
  • Resistance Level
  • RDHL $6.26
  • BREA $0.68
  • Average True Range (ATR)
  • RDHL 0.29
  • BREA 0.05
  • MACD
  • RDHL -0.02
  • BREA -0.01
  • Stochastic Oscillator
  • RDHL 7.69
  • BREA 18.29

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About BREA Brera Holdings PLC

Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.

Share on Social Networks: